Meeder Asset Management’s Vaxcyte PCVX Stock Holding History

Meeder Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.13K	Sell	71 -62	-47%	-$3.37K	﹤0.01%	872
2026 Q1	$7.73K	Buy	+133	New	+$7.22K	﹤0.01%	752
2025 Q3	–	Sell	-44	Closed	-$1.43K	–	911
2025 Q2	$1.43K	Buy	44 +2	+5%	+$66	﹤0.01%	826
2025 Q1	$1.59K	Sell	42 -10	-19%	-$800	﹤0.01%	880
2024 Q4	$4.26K	Sell	52 -646	-93%	-$64.1K	﹤0.01%	851
2024 Q3	$79.8K	Buy	698 +635	+1,008%	+$57.2K	0.01%	313
2024 Q2	$4.76K	Buy	63 +1	+2%	+$68	﹤0.01%	784
2024 Q1	$4.24K	Buy	+62	New	+$4.29K	﹤0.01%	651

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Meeder Asset Management's PCVX Position: Q2 2026 in Review

Meeder Asset Management reduced its Vaxcyte (PCVX) stake by 47% in Q2 2026, selling an estimated $3.37K and leaving 71 shares worth $4.13K. The position accounts for ﹤0.01% of the portfolio, ranked #872.

Meeder Asset Management first reported a position in PCVX in Q1 2024 and has held it in 8 quarters since. The position peaked at $79.8K in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Meeder Asset Management held 71 shares of Vaxcyte worth $4.13K as of Q2 2026.
Meeder Asset Management sold 62 Vaxcyte shares in Q2 2026, an estimated $3.37K.
Vaxcyte made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #872 holding.
Meeder Asset Management first reported a position in Vaxcyte in Q1 2024 and has held it in 8 quarters since.
Meeder Asset Management's Vaxcyte position peaked at $79.8K in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.